Home/Filings/4/0001012975-20-000033
4//SEC Filing

venBio Global Strategic Fund II L.P. 4

Accession 0001012975-20-000033

CIK 0001744659other

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 8:58 AM ET

Size

11.7 KB

Accession

0001012975-20-000033

Insider Transaction Report

Form 4
Period: 2020-01-13
Transactions
  • Sale

    Common Stock

    2020-01-13$20.23/sh494,000$9,993,6203,322,138 total(indirect: See footnote)
Transactions
  • Sale

    Common Stock

    2020-01-13$20.23/sh494,000$9,993,6203,322,138 total(indirect: See footnote)
Transactions
  • Sale

    Common Stock

    2020-01-13$20.23/sh494,000$9,993,6203,322,138 total(indirect: See footnote)
Transactions
  • Sale

    Common Stock

    2020-01-13$20.23/sh494,000$9,993,6203,322,138 total(indirect: See footnote)
Transactions
  • Sale

    Common Stock

    2020-01-13$20.23/sh494,000$9,993,6203,322,138 total(indirect: See footnote)
Footnotes (1)
  • [F1]These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.

Issuer

Akero Therapeutics, Inc.

CIK 0001744659

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001634632

Filing Metadata

Form type
4
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 8:58 AM ET
Size
11.7 KB